Newly discovered anti-inflammatory properties of the benzamides and nicotinamides

Molecular and Cellular Biochemistry

Volumn 193, Issue 1-2, 1999, Pages 119-125

  Pero, Ronald W ^a   Axelsson, Bengt ^b   Siemann, Dietmar ^c   Chaplin, David ^d   Dougherty, Graeme ^e  

^a LUND UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF FLORIDA   (United States)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

^e BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Benzamides; DNA repair; Inflammation; NF kB; Nicotinamides apoptosis

Indexed keywords

3 CHLOROPROCAINAMIDE; BENZAMIDE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METOCLOPRAMIDE; NICOTINAMIDE; PROCAINAMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CONFERENCE PAPER; DNA REPAIR; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; INFLAMMATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG EDEMA; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

ANIMALIA;

EID: 0032917035     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-1-4419-8740-2_18     Document Type: Conference Paper

References (30)

1. Stanley, Rotrosen (eds). The Benzamides: Pharmacology, Neurobiology and Clinical Aspects. Raven Press, New York, 1982
2. Horsman MR: Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. Acta Oncol 34: 571-587, 1995
3. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC: Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 25: 451-494, 1983
4. Pero RW, Olsson A, Amiri A, Chaplin D: Multiple modes of action of the benzamides and nicotinamides as sensitizers of radio- and chemotherapies. Opportunities for drug design. Cancer Prev Del 22(3): 225-236, 1998
5. King FD, Sanger GJ: 5-HT3 receptor antagonists. Drugs Future 14: 875-889, 1989
6. Pero RW, Olsson A, Sheng Y, Hua J, Mšller C, Kjellén E, Killander D, Marmor M: Progress in identifying clinical relevance of inhibition, stimulation and measurement of poly ADP-ribosylation. Biochimie 77: 385-393, 1995
7. Olsson A, Pero RW, Olofsson T: Specific binding and active transport of nicotinamide in human leukernic K562 cells. Biochem Pharmacol 45: 1191-1200, 1993
8. Olsson A, Sheng Y, Kjellén E, Pero RW: In vivo measurement of DNA damage, DNA repair and NAD pools as indicators of radiosensitization by metoclopramide. Carcinogenesis 16 (5): 1029-1035, 1995
9. Olsson A, Sheng Y, Pero RW, Chaplin D, Horsman M: DNA damage and repair in tumour and nontumour tissues of mice induced by nicotinamide. Brit J Cancer 74: 368-373, 1996
10. Pero RW, Olsson A, Simanaitis M, Amiri A, Andersen I: Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, Sensamiode and Neu-Sensamide. Pharmacol Toxicol 80: 231-239, 1997
11. Olsson AK, Hua J, Sheng Y, Pero RW: Neutral metoclopramide induces tumor cytotoxicity and sensitizes ionizing radiation of a human lung adenocarcinoma and virus induced sarcoma in mice. Acta Oncol 36 (3): 321-328, 1997
12. Jacobson MK, Cervantes-Lauran D, Strohm MS, Coyle DL, Bummer PM, Jacobson EL: NAD glycohydrolases and the metabolism of cyclic ADP-ribose. Biochimie 77: 341-344, 1995
13. Lee HC, Graef R, Walseth TF: Cyclic ADP-ribose and its metabolic enzymes. Biochimie 77: 345-355, 1995
14. alpha induced cell death. Science 274: 782-784, 1996
15. Wang C-Y, Mayo MW, Baldwin AS: TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kB. Science 274: 784-787, 1996
16. alpha-induced apotosis by NF-kB. Science 274: 787-789, 1996
17. Barnes PJ, Adcock IM: NF-kB: A pivotal role in asthma and a new target for therapy. TIPS 18: 46-50, 1997
18. Robert-Piessard S, LeBaut G, Courant J, et al.: Non-acidic anti-inflammatory compounds: Activity of N-(4-6-dimethyl-2-pyridinyl) benzamides and derivatives. Eur J Med Chem 25: 9-19, 1990
19. Moffett RB, Robert A, Skaletzky LL: Antiulcer agents, p-amino-benzamido aromatic compounds. J Med Chem 14 (10): 963-968, 1971
20. Piriou R, Petit JY, Welin I: Benzamide potentiation of behavioral apomorphine-induced effects: Mechanism involved. Experientia 41: 1409-1410, 1985
21. Bouhayat S, Piessard S, LeBaut G, Sparfel L, Petit J-Y, Piriou F, Welin I: Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyrindyl) benzamides. J Med Chem 28: 555-559, 1985
22. Sampaio ER, Sarno EN, Galilly Z, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Med Chem 173: 699-703, 1991
23. Nishimura K, Hashimoto Y, Iwasaki S: Enhancement of phorbol ester-induced production of tumor necrosis factor alpha by thalidomide. Biochem Biophys Res Commun 199 (2): 455-460, 1994
24. Rankin PW, Jacobson EI, Benjamin RC, Moss J, Jacobson M: Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J Biol Chem 264 (8): 4312-4317, 1989
25. Hirst DG, Joiner B, Hirst VK: Blood flow modification by nicotinamide and metoclopramide in mouse tumors growing in different sites. Br J Can 67: 1-6, 1993
26. Pellat-Deceurtynick C, Wietzerbin J, Drapier J-C: Nicotinamide inhibits nitric oxide synthase mRNA induction in acitvated macrophages. Biochem J 297: 53-58, 1994
27. Wu H, Lozano G: NF-kB activation of p53. J Biol Chem 269: 20067-20074, 1994
28. Graeber TG, Osamanian C, Jacks T, Houseman DE, Giaccia AJ: Hypoxia mediated selection of cells with diminished apoptoic potential in solid tumours. Nature 379: 88-91, 1996
29. Keiser A, Weich HA, Brandner G, Marme D, Kolch W: Mt p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9: 963-969, 1994
30. Poirier GG, Moreau P (eds): ADP-ribosylation reactions. Springer-Verlag, New York, pp. 1-410, 1992